Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial-Reference-Cited by-同舟云学术

Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial

Published:2016-09-20 Issue:2 Volume:6 Page:164-172
ISSN:2048-8726
Container-title:European Heart Journal: Acute Cardiovascular Care
language:en
Short-container-title:European Heart Journal: Acute Cardiovascular Care

Author:

Kosova Ethan C¹,Bonaca Marc P²,Dellborg Mikael³,He Ping²,Morais Joao⁴,Oude Ophuis Ton⁵,Scirica Benjamin M²,Tendera Michal⁶,Theroux Pierre⁷,Braunwald Eugene²,Morrow David A²

Affiliation:

1. Department of Medicine, Brigham and Women’s Hospital, Boston, USA

2. TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, USA

3. Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden

4. Santo Andre’s Hospital, Leiria, Portugal

5. Canisius–Willhelmina Hospital, Nijmegen, The Netherlands

6. Third Division of Cardiology, Medical University of Silesia, Katowice, Poland

7. Montreal Heart Institute, University of Montreal, Canada

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/2048872616644910

Reference26 articles.

1. Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects

2. Vorapaxar in the Secondary Prevention of Atherothrombotic Events

3. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

4. New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo

5. Vorapaxar in Patients With Peripheral Artery Disease

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment;Journal of Cardiovascular Development and Disease;2022-11-16

2. Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events – A Review on Vorapaxar;Current Problems in Cardiology;2021-10

3. Improving Outcomes in Cardiovascular Diseases;Cardiology in Review;2021-03-19

4. Vorapaxar in the treatment of cardiovascular diseases;Future Cardiology;2020-09

5. The myth of ‘stable’ coronary artery disease;Nature Reviews Cardiology;2019-07-29